Genprex Inc

For the period ended Dec 31, 2024. Filed Apr 1, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Apr 1, 2025

GNPX$2.06-0.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Changes in Stockholders’ Equity

Common Stock
	Shares	Amount	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at December 31, 2022	1,202,677	$1,203	$125,101,356	$(102,827,819)	$22,274,740
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	282,725	282	10,593,095	—	10,593,377
Issuance of common stock for services	500	1	19,009	—	19,010
Share-based compensation	—	—	5,389,718	—	5,389,718
Net loss	—	—	—	(30,860,461)	(30,860,461)
Balance at December 31, 2023	1,485,902	$1,486	$141,103,178	$(133,688,280)	$7,416,384
Issuance of common stock, pre-funded warrants, and warrants for cash, net of issuance costs	9,227,065	9,227	12,002,726	—	12,011,953
Issuance of common stock for services	51,375	51	206,934	—	206,985
Company issued rounding of street name accounts for reverse stock split	64,690	65	(65)	—	—
RSUs conversion to common stock	31,623	32	(33)	—	(1)
Share-based compensation	—	—	3,095,997	—	3,095,997
Deemed dividend related to warrant modification	—	—	(277,119)	—	(277,119)
Warrant Modification	—	—	277,119	—	277,119
Net loss	—	—	—	(21,111,163)	(21,111,163)
Balance at December 31, 2024	10,860,655	$10,861	$156,408,737	$(154,799,443)	$1,620,155

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.